Suppr超能文献

幽门螺杆菌感染和消化性溃疡疾病的高效每日两次三联疗法:体外甲硝唑耐药性有临床相关性吗?

Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?

作者信息

Lerang F, Moum B, Haug J B, Tolås P, Breder O, Aubert E, Høie O, Søberg T, Flaaten B, Farup P, Berge T

机构信息

Department of Internal Medicine, Ostfold Central Hospital, Fredrikstad, Norway.

出版信息

Am J Gastroenterol. 1997 Feb;92(2):248-53.

PMID:9040200
Abstract

OBJECTIVES

To compare cure rates of Helicobacter pylori (H. pylori) infection, ulcer healing, and side effects of three simplified regimens of triple therapy in patients with peptic ulcer disease.

METHODS

Two hundred thirty-one patients were prospectively randomized to receive either regimen OAM (omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 400 g b.i.d.), OCM (omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., and metronidazole 400 mg b.i.d.), or BCM (bismuth subcitrate 240 mg b.i.d., clarithromycin 250 mg b.i.d., and metronidazole 400 mg b.i.d.), all for 10 days. Side effects were reported immediately afterward in a self-administered questionnaire. Upper endoscopy was carried out before treatment and 2 months after treatment. Three antral and three corpus biopsy specimens were analyzed microbiologically and with rapid urease test to determine the presence of H. pylori. Altogether 143 patients (62%) had an active ulcer at start of treatment. Metronidazole resistant (M-R) H. pylori strains were found in 30% of patients, while none had clarithromycin resistant (C-R) strains.

RESULTS

According to intention-to-treat analysis, H. pylori cure rates were 91, 95, and 95% with OAM, OCM, and BCM, respectively (p = 0.63). In patients with metronidazole-sensitive (M-S) strains versus M-R strains, the cure rates were 96 versus 77% with OAM (p = 0.025), 94 versus 94% with OCM, and 94 versus 96% with BCM. Ulcer healing rates were 95, 94, and 92%, respectively (p = 0.91). There were no significant differences in side effects between the regimens, and only five patients (2%) had to stop the treatment prematurely.

CONCLUSIONS

All treatment regimens were highly effective for cure of H. pylori infection and for ulcer healing. Metronidazole resistance reduced the efficacy of OAM, but was of no importance for the efficacy of OCM or BCM. Side effects were of minor importance.

摘要

目的

比较三种简化三联疗法对消化性溃疡患者幽门螺杆菌(H. pylori)感染的治愈率、溃疡愈合情况及副作用。

方法

231例患者被前瞻性随机分为接受OAM方案(奥美拉唑20mg,每日两次,阿莫西林750mg,每日两次,甲硝唑400mg,每日两次)、OCM方案(奥美拉唑20mg,每日两次,克拉霉素250mg,每日两次,甲硝唑400mg,每日两次)或BCM方案(枸橼酸铋钾240mg,每日两次,克拉霉素250mg,每日两次,甲硝唑400mg,每日两次),均治疗10天。治疗结束后立即通过自行填写问卷报告副作用情况。在治疗前及治疗后2个月进行上消化道内镜检查。采集三块胃窦和三块胃体活检标本进行微生物学分析及快速尿素酶试验,以确定是否存在幽门螺杆菌。共有143例患者(62%)在治疗开始时患有活动性溃疡。30%的患者发现有甲硝唑耐药(M-R)幽门螺杆菌菌株,而无一例有克拉霉素耐药(C-R)菌株。

结果

根据意向性分析,OAM、OCM和BCM方案的幽门螺杆菌治愈率分别为91%、95%和95%(p = 0.63)。在甲硝唑敏感(M-S)菌株与M-R菌株的患者中,OAM方案的治愈率分别为96%和77%(p = 0.025),OCM方案为94%和94%,BCM方案为94%和96%。溃疡愈合率分别为95%、94%和92%(p = 0.91)。各方案之间副作用无显著差异,只有5例患者(2%)不得不提前终止治疗。

结论

所有治疗方案对幽门螺杆菌感染的治愈及溃疡愈合均高度有效。甲硝唑耐药降低了OAM方案的疗效,但对OCM或BCM方案的疗效无影响。副作用影响较小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验